Farxiga (dapagliflozin)
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)
June 2016
CONTRAINDICATIONS
Update phrase end-stage renal disease (ESRD) to (eGFR less than 30 mL/min/1.73 m2) end-stage renal...
Source: Drugs.com - Labeling Changes - Category: Drugs & Pharmacology Source Type: alerts